Astellas Institute for Regenerative Medicine

CureDuchenne Ventures Invests in MyoGene Bio and its AAV-Delivered CRISPR/Cas9 Gene Editing Approach

Retrieved on: 
Thursday, May 11, 2023
Myogenic determination factor 5, CRISPR, Duchenne muscular dystrophy, Gene editing, Research, Astellas Institute for Regenerative Medicine, AAV, Doctor of Philosophy, Regenerative medicine, DMD, Patient, Investment, CIRM, Exon, Disease, Pharmaceutical industry, Vaccine, Duchenne

NEWPORT BEACH, Calif., May 11, 2023 /PRNewswire/ -- CureDuchenne Ventures announced funding for MyoGene Bio, LLC, a biotech company developing a novel gene editing therapy for Duchenne muscular dystrophy (DMD).

Key Points: 
  • NEWPORT BEACH, Calif., May 11, 2023 /PRNewswire/ -- CureDuchenne Ventures announced funding for MyoGene Bio, LLC, a biotech company developing a novel gene editing therapy for Duchenne muscular dystrophy (DMD).
  • MyoGene will use this funding to advance development of MyoDys45-55, an AAV-delivered CRISPR/Cas9 gene editing approach that would be applicable to up to 50 percent of all DMD patients.
  • The rationale for this approach comes from clinical cases of individuals naturally lacking this hotspot region between exons 45 and 55.
  • "CureDuchenne Ventures has a long history of investing in gene therapy and gene editing research to treat DMD, and MyoGene Bio's approach is an excellent application of CRISPR/Cas9 technology to potentially address a large proportion – up to half – of DMD cases," said Debra Miller, founder and chief executive officer of CureDuchenne.

AceLink Therapeutics Appoints Pedro Huertas, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Monday, May 8, 2023
General Health, Pharmaceutical, Health, Clinical Trials, Biologics license application, B cell, Therapy, Doctor of Philosophy, Harvard University, Stanford University, Astellas Institute for Regenerative Medicine, MIT Sloan School of Management, Quality of life, Research, Rheumatology, CMO, Harvard Medical School, Developmental Biology (journal), StemCells, Inc., Patient, Palliative care, Internal medicine, Cell, Hospital, Rare, Amicus Therapeutics, FDA, Massachusetts General Hospital, Strong, DSM-IV codes, Pfizer, Pharmaceutical industry, Genzyme, Biochemistry

Dr. Huertas is a distinguished expert in rare diseases and will serve as an important resource for AceLink as the company advances its development pipeline.

Key Points: 
  • Dr. Huertas is a distinguished expert in rare diseases and will serve as an important resource for AceLink as the company advances its development pipeline.
  • “We are thrilled to welcome Dr. Huertas to our executive team during a pivotal time, as our lead asset, AL01211, enters into two Phase 2 clinical trials later this year,” said Jerry Shen, Ph.D., Chief Executive Officer and Founder of AceLink Therapeutics.
  • Rarely one finds a company that manages its assets so well and the exciting Phase 1 data collected positions AceLink to further advance AL01211 into Phase 2 studies,” said Pedro Huertas, M.D., Ph.D., Chief Medical Officer of AceLink.
  • Prior to joining AceLink, Dr. Huertas was Chief Medical Officer for Eloxx Pharmaceuticals, Sentien Biotechnologies, Inozyme Pharma, Novazyme Pharmaceuticals, and Kriya Therapeutics.

Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

Retrieved on: 
Tuesday, May 2, 2023
Obsidian, Xenon, Amgen, Astellas Institute for Regenerative Medicine, Partnership, Therapy, Stryker, Senior, Doctor of Philosophy, Senior advisor, Paul's walk, ASX, Fertility preservation, Patient, Ernst, Growth, Entrepreneurship, Dimension, Medtech, Ernst & Young Entrepreneur of the Year Award, Pharmaceutical industry, Astellas Pharma, Halozyme

Dr. Wotton fills the role of Independent Director of the Board, created following Dimension's Series A raise of $15M completed in February 2023.

Key Points: 
  • Dr. Wotton fills the role of Independent Director of the Board, created following Dimension's Series A raise of $15M completed in February 2023.
  • He brings an expert perspective on platform growth opportunities as a leader of multiple global biotechnology and pharmaceutical companies.
  • Dr. Wotton is a serial entrepreneur and inventor with experience spanning scientific research, product development, and transformational business transactions.
  • Chris Ehrlich joins the company as Senior Advisor focusing on corporate development and financial strategy.

Combined Therapeutics Expands Board of Directors with Appointments of Biopharma Industry Veterans Paul Wotton, Robert Ruffolo and Kevin F. McLaughlin

Retrieved on: 
Wednesday, March 8, 2023
Obsidian, TIL, Pharmacology, MBA, Research, Astellas Pharma, Heart, Therapy, University, Acquisition, Biotechnology, Babson College, Growth, Accounting, Clinical trial, MPH, Discoverer, Infection, Drug discovery, Pharmacy, Messenger, GSK, Robert Paul, Wyeth, CTX, Melanoma, Astellas Institute for Regenerative Medicine, Acceleron Pharma, Carvedilol, GSK plc, Ohio State University, Merck, Combined, University College London, Book, Overalls, Pharmaceutical industry, Vericel, Northeastern University, Doctor of Philosophy

"We are finalizing our financing round and putting in place the infrastructure to advance our mRNA vaccines and therapeutics into clinical development.

Key Points: 
  • "We are finalizing our financing round and putting in place the infrastructure to advance our mRNA vaccines and therapeutics into clinical development.
  • Dr. Wotton is a serial entrepreneur and inventor with more than 30 years of experience in the biotech and pharma industries.
  • He currently serves on the boards of Vericel, Cynata Therapeutics and Kytopen, and is a co-founder and director of Avenge Bio.
  • Mr. McLaughlin is a finance and management executive with more than 40 years of experience in the biopharma and high tech industries.

Slone Partners Places Paul Wotton, Ph.D. as Chair of Board of Directors at Kytopen

Retrieved on: 
Friday, January 13, 2023
Entrepreneurship, University, Pharmacy, Ernst & Young Entrepreneur of the Year Award, Biotechnology, Ernst, Knowledge, MIT, Marketing, ASX, Astellas Institute for Regenerative Medicine, Pharmaceutical industry, Management

SOUTH RIDING, Va., Jan. 13, 2023 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Paul K. Wotton, Ph.D., as Chair of the Board of Directors at Kytopen, an MIT startup biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms.

Key Points: 
  • He currently serves on the Board of Directors of Vericel Corporation (NASDAQ: VCEL) and Cynata Therapeutics (ASX: CYP) and is a founder of Avenge Bio.
  • "Paul Wotton is an extremely accomplished and talented leader and visionary in biotech, advanced cell technology, and biopharmaceutical research, discovery, and marketing," said Slone Partners CEO Leslie Loveless .
  • "He brings tremendous passion and depth of knowledge to his new role as Chair of the Board of Directors at Kytopen."
  • "We are thrilled to welcome Paul Wotton to join and lead the Kytopen Board of Directors," said Dr. Paulo Garcia , CEO and Co-Founder of Kytopen.

Regenerative Medicine in Pharma Market to Grow by 11.1% Annually Through 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 19, 2022
Health, Pharmaceutical, Astellas Institute for Regenerative Medicine, Table, Administration, US, Gerber Products Company, Injection (medicine), Route of administration, Regenerative medicine, Prevalence, Plasma protein binding, Conditional sentence, Corticosteroid, Cancer, Pharmaceutical industry, Fine chemical, Pharma

The Regenerative Medicine in Pharma market size was valued at US$29.4 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during 2022-2027.

Key Points: 
  • The Regenerative Medicine in Pharma market size was valued at US$29.4 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during 2022-2027.
  • The Regenerative Medicine in Pharma market report provides an executive-level overview of the regenerative medicine market worldwide today, with detailed forecasts of key indicators up to 2027.
  • Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the drug class segments.
  • Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the route of administration segment.

Regenerative Medicine in Pharma Market Size, Share and Trends Analysis by Region, Drug Class, Route of Administration, and Segment Forecast, 2022-2027

Retrieved on: 
Friday, December 9, 2022
Regenerative medicine, Gerber Products Company, Conditional sentence, Astellas Institute for Regenerative Medicine, Injection (medicine), Prevalence, Cancer, Plasma protein binding, US, Route of administration, Administration, Table, Corticosteroid, Pharmaceutical industry, Fine chemical, Pharma

The Regenerative Medicine in Pharma market report provides an executive-level overview of the regenerative medicine market worldwide today, with detailed forecasts of key indicators up to 2027.

Key Points: 
  • The Regenerative Medicine in Pharma market report provides an executive-level overview of the regenerative medicine market worldwide today, with detailed forecasts of key indicators up to 2027.
  • - Overview of regenerative medicine in pharma market including industry trends, funding & deals, pipeline analysis, regulatory details, and product & company profile
    - Regenerative medicine in pharma market outlook: analysis as well as historical figures and forecasts of revenue opportunities from the product, technology, application, and geographic segments.
  • - Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the drug class segments.
  • - Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the route of administration segment.

Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001

Retrieved on: 
Thursday, September 22, 2022
Other Manufacturing, Research, Clinical Trials, Stem Cells, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Oncology, Institute, Regenerative medicine, Chimeric antigen receptor T cell, Time, Quality control, ATMP, Advanced Therapy Medicinal Product, CGMP, ADI, Stem cell, CAR, Partnership, Immunotherapy, NK, Patient, Ministry of Education (Malaysia), FUI, Technology, SAS, Cell, CDMO, Lymphatic system, Contract, Microsoft, Multimedia, Lymphoma, GMP, Astellas Institute for Regenerative Medicine, University Hospital Center Dr Dragiša Mišović, Vaccine, Fine chemical, Pharmaceutical industry, Exosome

Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercells lead product.

Key Points: 
  • Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercells lead product.
  • Its patented manufacturing process allows a complete industrialization by using the same batch of NK cells for multiple patients.
  • Cell-Easy is an analytics-driven Contract Development and Manufacturing Organization (CDMO) specialized in the production of Gene-modified Cell and Cell Therapy products.
  • Emercell has signed a strategic agreement with Cell-Easy specialized in the development and production of ATMP.

Onward Therapeutics Made a Second Strategic Equity Investment in Emercell for Their NK Cell Technology in Cancer Immunotherapy

Retrieved on: 
Monday, June 20, 2022
ADI, Lymphatic system, NK, FUI, Drug development, Regenerative medicine, Technology, University Hospital Center Dr Dragiša Mišović, CEO, Lymphoma, Institute, ICM, Astellas Institute for Regenerative Medicine, CAR, Company, Cancer, Exercise, Natural killer T cell, Patient, Chimeric antigen receptor T cell, Therapy, Vaccine, Pharmaceutical industry, Épalinges, Biopôle

EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /PRNewswire/ --Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emercell) announced today the recent exercise of Onward Therapeutics' second of three instalments of equity investment in Emercell.

Key Points: 
  • EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /PRNewswire/ --Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emercell) announced today the recent exercise of Onward Therapeutics' second of three instalments of equity investment in Emercell.
  • Emercell has developed a platform technology to produce off-the-shelf natural killer (NK) cells.
  • NK-001 is an optimized cell therapy product consisting of highly activated and alloreactive allogeneic NK cells.
  • Onward Therapeutics is an oncology company focusing on the identification and development of innovative medicines for the treatment of cancer.

ExCellThera announces submission of Drug Master File for UM171

Retrieved on: 
Friday, June 17, 2022
Solution, Degenerative disease, Type, FDA, Regenerative medicine, B cell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lymphatic system, LSD1, Research, New Drug Application, Protein, GLOBE, Potency (pharmacology), DMF, Rejuvenation, Stem cell, Adult, Food, PSC, Patient, Food and Drug Administration, Astellas Institute for Regenerative Medicine, Pharmaceutical industry, IND

UM171 is a small molecule that leads to specific epigenetic modifications which have a profound impact on hematopoietic stem cell self-renewal.

Key Points: 
  • UM171 is a small molecule that leads to specific epigenetic modifications which have a profound impact on hematopoietic stem cell self-renewal.
  • UM171 has been cited in several scientific publications, and its mechanism of action was published in 2021 in the peer-reviewed journal, Cell Stem Cell.
  • ExCellThera has developed pre-formulated commercial-grade UM171 single-use vials that can be integrated into the manufacturing process of various cell and gene therapy products as a reagent.
  • A Drug Master File (DMF) is a submission to the Food and Drug Administration (FDA) that may be used to provide confidential detailed information about facilities, processes or materials used in the manufacturing, processing, packaging, and storing of human drugs and biologics.